Cargando…

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making. We report results from GALAXY, which is an obse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotani, Daisuke, Oki, Eiji, Nakamura, Yoshiaki, Yukami, Hiroki, Mishima, Saori, Bando, Hideaki, Shirasu, Hiromichi, Yamazaki, Kentaro, Watanabe, Jun, Kotaka, Masahito, Hirata, Keiji, Akazawa, Naoya, Kataoka, Kozo, Sharma, Shruti, Aushev, Vasily N., Aleshin, Alexey, Misumi, Toshihiro, Taniguchi, Hiroya, Takemasa, Ichiro, Kato, Takeshi, Mori, Masaki, Yoshino, Takayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873552/ https://www.ncbi.nlm.nih.gov/pubmed/36646802 http://dx.doi.org/10.1038/s41591-022-02115-4

Ejemplares similares

CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer
por: Taniguchi, Hiroya, et al.
Publicado: (2021)

DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy
por: Miyo, Masaaki, et al.
Publicado: (2022)

Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study
por: Kotani, Daisuke, et al.
Publicado: (2021)

Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer
por: Miyo, Masaaki, et al.
Publicado: (2020)

Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
por: Chida, Keigo, et al.
Publicado: (2022)

REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2021)

Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials
por: Yukami, Hiroki, et al.
Publicado: (2022)

Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors
por: Kasi, Pashtoon M., et al.
Publicado: (2022)

A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial
por: Yoshida, Yoichiro, et al.
Publicado: (2015)

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
por: Mishima, Saori, et al.
Publicado: (2019)

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
por: Kubota, Y., et al.
Publicado: (2023)

Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
por: Ishibashi, Keiichiro, et al.
Publicado: (2021)

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
por: Soda, Hitoshi, et al.
Publicado: (2015)

Structural analysis of β-glucosidase mutants derived from a hyperthermophilic tetrameric structure
por: Nakabayashi, Makoto, et al.
Publicado: (2014)

Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer
por: Sasaki, Akinori, et al.
Publicado: (2020)

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
por: Ishii, Takahiro, et al.
Publicado: (2020)

Sustainable Clinical Development of Adjuvant Chemotherapy for Colon Cancer
por: Oki, Eiji, et al.
Publicado: (2021)

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial
por: Yoshino, Takayuki, et al.
Publicado: (2019)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

Hybrid Repair for Mega-Aortic Syndrome due to Giant Cell Aortitis in a Heart Failure Patient
por: Inoue, Takehiro, et al.
Publicado: (2020)

A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer
por: Bando, Hideaki, et al.
Publicado: (2019)

Correction: A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer
por: Bando, Hideaki, et al.
Publicado: (2020)

Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial)
por: Kotaka, Masahito, et al.
Publicado: (2015)

Real‐world data on microsatellite instability status in various unresectable or metastatic solid tumors
por: Akagi, Kiwamu, et al.
Publicado: (2021)

Multiple Forms of Glutamate Dehydrogenase in Animals: Structural Determinants and Physiological Implications
por: Bunik, Victoria, et al.
Publicado: (2016)

Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2022)

Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial
por: Kuboki, Yasutoshi, et al.
Publicado: (2023)

BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2020)

SCRUM‐Japan GI‐SCREEN and MONSTAR‐SCREEN: Path to the realization of biomarker‐guided precision oncology in advanced solid tumors
por: Nakamura, Yoshiaki, et al.
Publicado: (2021)

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma
por: Mishima, Saori, et al.
Publicado: (2018)

Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
por: Satake, Hironaga, et al.
Publicado: (2020)

A new crystal form of a hyperthermophilic endocellulase
por: Kataoka, Misumi, et al.
Publicado: (2014)

A Fungal Metabolite Asperparaline A Strongly and Selectively Blocks Insect Nicotinic Acetylcholine Receptors: The First Report on the Mode of Action
por: Hirata, Koichi, et al.
Publicado: (2011)

Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer
por: Taniguchi, Hiroya, et al.
Publicado: (2021)

Precision Oncology and the Universal Health Coverage System in Japan
por: Ebi, Hiromichi, et al.
Publicado: (2019)

Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer
por: Kotaka, Masahito, et al.
Publicado: (2018)

Monitoring FTD in the peripheral blood mononuclear cells of elderly patients with metastatic colorectal cancer administered FTD plus bevacizumab as first‐line treatment
por: Fujimoto, Yoshiaki, et al.
Publicado: (2021)

The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies
por: Sawada, Kentaro, et al.
Publicado: (2018)

Structural Basis for the Binding of Allosteric Activators Leucine and ADP to Mammalian Glutamate Dehydrogenase
por: Aleshin, Vasily A., et al.
Publicado: (2022)

Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study
por: Kato, Takeshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ie11alksshqllad36mlpsee51g